The Novo Nordisk share increases by 7 %after the latest drug for weight loss from the manufacturer Ozempic is promising




The new treatment aims at the intestinal hormone GLP-1, but also adds Amylin, a hormone that is distributed by the pancreas and suppresses hunger. Read more



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *